Hepatitis C viral (HCV) infection is a significant public health problem. In the UK, an estimated 200,000 individuals have active HCV infection, most of whom are injecting drug users (IDUs). Many IDUs spend time within the prison system therefore screening for HCV infection in this setting is important. However, uptake of testing within prisons is very low.
Qualitative interview study. 30 interviews with 25 male and 5 female prisoners with a history of injecting drug use.
Personal and institutional barriers to uptake of testing for HCV were identified. Personal barriers included: prisoners' fears and lack of knowledge about HCV, low motivation for testing, lack of awareness about the testing procedure, and concerns about confidentiality and stigma. Institutional barriers included: the prisons' applications procedure for testing, inadequate pre- and post-test discussion, lack of pro-active approaches to offering testing, and lack of continuity of care on discharge and transfer.
This study highlights potential areas of development in the management of HCV in prisons. Further research is needed to evaluate care pathways for HCV in the prison setting and to develop and assess interventions to improve the uptake of testing for HCV by prisoners.
Hepatitis C viral (HCV) infection is a significant public health problem. Chronic infection, if left untreated, can lead to serious illness in the long-term such as cirrhosis and cancer of the liver. In England, the estimated prevalence of active HCV infection is 0.4%, equating to 200,000 cases. The overwhelming burden of disease is associated with injecting drug use (IDU), which is identified as a risk factor in over 80% of cases. Amongst IDUs, HCV prevalence rates of 40–80% have been reported[3, 4]. The custodial setting has a high proportion of prisoners with a history of IDU; estimated at around 24%. Up to 61% of IDUs have spent time within the prison system.
The Hepatitis C Strategy for England, 2002, encourages testing for HCV in high risk populations. There is good evidence that selective testing for HCV in IDUs, is effective in the long-term. A recent study demonstrated the cost-effectiveness of screening for HCV in the prison population. Whilst in prison, IDUs lead a less chaotic life than they would in the community. Hence, the prison setting is an important environment to offer health promotion and treatment interventions.
Although HCV testing is available in the prison healthcare system, the uptake of such opportunities is low; Skipper et al reported an uptake rate amongst prisoners of only 8.5%. The reasons for this low uptake are not known. The purpose of this study was to identify the factors that influence the uptake of testing for HCV infection by prisoners. Knowledge of these barriers will help to optimise the ways in which testing opportunities are made available to prisoners.
This was a qualitative study using audio-recorded semi-structured interviews in a sample of purposively selected prisoners. Participants were recruited from three prisons in Northeast England: HMP Durham; HMP Frankland and HMP Low Newton (Table 1). Prisoners were eligible if they were aged 18 years or over, had injected drugs in the past and were able to communicate in English. At HMP Frankland prisoners with a history of injecting drug use were identified from referrals to the Counselling, Assessment, Referral, Advice and Throughcare Service (CARATS). Eligible participants at HMP Durham were identified from referrals to the detoxification service. At HMP Low Newton participants were identified from data obtained from the Grubin Tool health assessment completed on reception.
The interview schedule was developed through consultation with a project steering group, comprising prison healthcare staff, specialists in communicable disease control, and representatives from Primary Care Trusts and Drug and Alcohol Action Teams. Prisoners were provided with information sheets about the study and asked to give written consent to participate in the study prior to interview. Information and consent documents made clear that participation or non-participation in the study would not prejudice nor enhance their treatment in the prison. No reimbursement or inducements were offered to prisoners.
All prisoners were interviewed by LS in the health care facility at each establishment. LS was accompanied by a CARATS worker who acted as advocate for the prisoner. Interviews lasted between 10 and 40 minutes. All interviews were audio-recorded (with the prisoner's consent), transcribed, and then checked for accuracy against the recording. The research team (LS, MJM, FMK) analysed transcripts using established procedures of constant comparative analysis from which themes were developed from the participants' responses.
The study was reviewed and given a favourable opinion by the Northern and Yorkshire Multi-centre Research Ethics Committee (MREC number: 04MRE0384). The study was approved by the Prisons Research Applications and Ethics Panel (PRAEP).
Ninety-nine eligible prisoners were identified. Fifty-five declined to participate. Forty-four initially agreed to participate but of these 10 declined to participate on the day, three were transferred to another institution prior to interview and one was held in a segregation unit during the available interview period. 30 prisoners took part in the study; 25 male and five female. Table 2 demonstrates that 19 participants had already taken up opportunities for HCV testing, most whilst in the prison system.
Interviews identified personal and institutional barriers to the uptake of testing for HCV. Personal barriers related predominantly to lack of knowledge and fear of disease, a lack of awareness about the testing procedure, disease prognosis, treatment and outcome, and concern about confidentiality and stigma. Motivation was a personal factor that could facilitate uptake of testing. Institutional barriers related to the application to request a test, inadequate pre- and post- test discussion, and lack of continuity of care in the event of discharge or transfer from prison.
'Cause they're maybes scared, scared of knowing'
Ignorance and fear of disease was common amongst participants. Many were not aware of disease prognosis, treatment options and outcomes. Some assumed that a positive diagnosis was a 'death sentence' (See Geoff, Table 3).
HCV was often conflated or formed a constellation with other blood borne viruses such as HIV. There was confusion about mode of transmission and likely prognosis (See Andy, Table 3).
Perception of risk was mixed. Some prisoners attached great significance to sexual promiscuity whilst others, although recognising the dangers of sharing needles and syringes, did not always appreciate the risks involved in sharing other paraphernalia (See Danny, Table 3).
'You bear a responsibility not to pass it on'
The main motivations for testing were discussed in terms of social or personal responsibility. Some of those who had had the test were unaware of potential treatments but had undertaken the test to determine whether they needed to take action to avoid infecting others (See Emma(a), Table 3).
'They couldn't get any blood out of me'
Some prisoners complained that health care personnel lacked the skills required to take venous blood; although some acknowledged that the poor state of their veins contributed to poor venous access. Several prisoners had had to take their own blood because nursing or medical staff were unable to do so. (See Chrissie, Table 3)
Prisoners were not usually aware of how the test would be carried out, but this did not appear to be a barrier in itself. Most of those who were aware that testing would involve venepuncture felt that prisoners were not likely to be frightened of needles. Prisoners were not aware of the availability of a buccal swab or finger-prick blood-test.
'You don't want the whole wing to know'
There were concerns that confidentiality would not be maintained after accessing healthcare. These concerns were related to a fear of stigmatisation. Prisoners were concerned about the level of detail that they had to provide to apply for a test and about who might have access to these details (see Tony, Table 3).
The problem of stigmatisation was related to IDU and HCV infection (see Emma(b), Table 3). Prisoners were concerned that they may be stigmatised if there was a large bruise resulting from failed attempts at venepuncture, which would then be apparent to other prisoners and prison officers. Prisoners were more likely to attribute HCV infection to sexual promiscuity rather than to IDU (see Gary, Table 3).
'You have to put an app in. An app!!'
Prisoners were required to complete an application form ('app') for access to health care, including HCV testing. Many prisoners regarded the 'app' as unnecessarily bureaucratic and a barrier to testing in terms of a requirement to disclose IDU and the long waiting time (see Alison, Table 4). One prisoner had made three applications for a test and had not been tested.
'I think someone should be there to talk to you about it... he didn't tell us nowt [nothing]"
Although some prisoners reported that they had had the opportunity for pre- and post-test discussion with a healthcare professional, this was not always the case (see Emma, Table 4). In some cases test results were 'posted' to prisoners under their cell door without post-test information and discussion. Several prisoners, like Emma, compared the availability of 'counselling' with that provided before and after HIV testing and thought that the procedure was more robust for HIV than for HCV.
'I was just trying to get through my rattle [detox]. That's all I were thinking about'
The offer of testing opportunities may not arise at an appropriate time. Prisoners with short sentences or who are on remand (ie. awaiting trial) might not be able to keep their appointments for testing because of court appearances or early discharge. Some prisoners could not recall whether they had been offered a test because they had other priorities at first reception to prison or because they were suffering the effects of drug/alcohol withdrawal at the time (see Chrissie, Table 4).
'I got shipped out, so it never really happened'
Prisoners felt that there was not always adequate communication and transfer of information between prisons or between prisons and healthcare in the community. A prisoner, waiting for the test in one prison prior to transfer, would have to re-apply at the new prison. Two prisoners changed their minds about testing and had not reapplied after transfer as they would have to wait. Other prisoners were concerned that treatments or interventions initiated in the community would not be followed up in prison (see Jimmy, Table 4).
'in here you wait like you wouldn't in the community'
Some prisoners felt that they might not have the same access to healthcare for Hepatitis C whilst in prison as they would do in the community (see Colin, Table 4). Others believed that poor access to healthcare was encountered in prison and in the community because of stigma relating to IDU (see Danny, Table 4).
This project has identified personal and institutional barriers in participants' discourse that could explain the poor uptake of testing for HCV by prisoners. Personal barriers included: prisoners' fears and lack of knowledge about HCV, lack of awareness about the test procedure, and concerns about confidentiality and stigma. Institutional barriers included: the prisons' applications procedure for testing, inadequate pre- and post-test discussion, lack of appropriate approaches to offering testing, and lack of continuity of care on discharge and transfer.
There are many benefits in the early diagnosis of HCV infection: Knowledge of the status of HCV infection may reduce risk behaviour[11, 12]; anti-viral treatment can eradicate infection in 40–85% of cases depending on viral genotype; secondary preventive measures, such as reducing alcohol intake, can reduce the risk of developing hepatocellular carcinoma; and the need for other health protection interventions, such as Hepatitis B and Hepatitis A vaccination may be identified. Yet, the majority of those with HCV infection remain undiagnosed; in England, fewer than 20% of those infected are diagnosed.
This study is not unique in identifying a poor understanding of HCV infection amongst IDUs. It is possible that increasing the awareness of the disease and the benefits of diagnosis will increase the uptake of testing.
We know that the uptake of testing for HCV by prisoners is low and that there is a higher prevalence of HCV amongst the prison population because of the higher proportion of injecting drug users in the custodial environment. This study demonstrates that: personal and institutional barriers may adversely affect the uptake of testing for HCV in prisons; there is general lack of awareness and fear of HCV amongst prisoners with a history of injecting drug use; prisoners are concerned about the potential for breaches in clinical confidentiality and about the stigma associated with a diagnosis of HCV. These findings will enable development of interventions to improve the uptake of testing for HCV in prisons and to develop care pathways that provide seamless healthcare within and outside the custodial setting.
Limitations of this study
Participants were recruited from three prisons with representation from male and female prisoners, and long-stay and short-stay establishments. However, only five women prisoners were interviewed, none from long-stay prisons. Although there is a potential for bias because data saturation was not reached amongst female participants, nevertheless, the interviews elicited a wide spectrum of opinion and experience. The presence of CARATs worker may have influenced the content and level of detail of the interviews. However, it appeared that prisoners were comfortable with the presence of the CARATs worker and in most cases appeared to have already established a degree of rapport with either an individual officer or the CARATs team in general.
One key limit to the study was that we were unable, within existing resources, to also interview prison personnel and health professionals working in the prisons to ascertain their views of barriers to uptake of HCV testing. We are therefore not able to identify potential disincentives for carrying out testing, for example the impact on resources of the potential added burden of care and treatment for those diagnosed with HCV. Nonetheless, this study is an example of effective collaborative working between multiple stakeholder organisations. A multidisciplinary steering group facilitated the recruitment of participants and conduct of the project.
This study has identified some factors that may contribute to the poor uptake of HCV testing in prisons. There is a need to develop approaches to increase the uptake of testing by raising awareness amongst prisoners about HCV infection, optimising testing pathways that support appropriate testing at appropriate times during a prisoner's stay in prison, ensuring adequate pre- and post-test discussion, and by developing care pathways for HCV that enable seamless continuity of care.
Noble A, Best D, Finch E, Gossop M, Sidwell C, Strang J: Injecting risk behaviour and year of first injection as predictors of hepatitis B and C status among methadone maintenance patients in south London. Journal of Substance Use. 2000, 5: 131-5.
Unlinked Anonymous Surveys Steering Group: Prevalence of HIV and hepatitis infections in the united Kingdom 2001. Annual report of the Unlinked Anonymous Prevalence Monitoring Programme. 2002, Department of Health, London
Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L: Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease & Public Health. 2000, 3: 121-6.
Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technology Assessment. 2002, 6: 1-122.
Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003, 52: 1500-4. 10.1136/gut.52.10.1500.
Rhodes T, Davis M, Judd A: Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004, 99: 621-33. 10.1111/j.1360-0443.2004.00692.x.
Kwiatkowski CF, Fortuin Corsi K, Booth RE: The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002, 97: 1289-94. 10.1046/j.1360-0443.2002.00208.x.
Craine N, Walker M, Carnwath T, Klee H: Hepatitis C testing and injecting risk behaviour: The results of a UK based pilot study. International Journal of Drug Policy. 2004, 15: 115-122. 10.1016/S0955-3959(02)00092-0.
National Institute for Health and Clinical Excellence (NICE): Technology appraisal Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. 2004, NICE, London
We wish to thank the National Treatment Agency for Substance Misuse for providing the funding for this study, members of the project steering group who helped develop and monitor the project, prison governors and prison healthcare workers for facilitating the recruitment of participants, CARATS workers for their advice and support, Durham and Chester le Street Primary Care Trust and North Tees Primary Care Trust for acting as research sponsors, Margaret Childs for transcribing the interviews, and the study participants for their time and cooperation.
Authors and Affiliations
North East Health Protection Unit, Health Protection Agency, Institute of Pathology, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
Institute of Health and Society, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
The author(s) declare that they have no competing interests.
LS carried out the interviews of participants; all authors contributed to the design of the study, data analysis and drafting of the manuscript; all authors read and approved the final manuscript.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Khaw, FM., Stobbart, L. & Murtagh, M.J.
'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners.
BMC Public Health7, 98 (2007). https://doi.org/10.1186/1471-2458-7-98